Q1 results: Dr Reddy’s profit rises seven-fold, beats forecast1 min read . Updated: 26 Jul 2018, 04:02 PM IST
Dr Reddy's Labs Q1 net profit rises to 476 crore in the quarter ended 30 June, compared with ₹66.6 crore a year earlier
Bengaluru: Indian generic drugmaker Dr.Reddy’s Laboratories Ltd posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the U.S. launch of a generic version of an opioid addiction drug.
Net profit came in at ₹ 476 crore ($69.31 million) in the quarter ended June 30, compared with ₹ 66.6 crore a year earlier, the company said. Analysts on average had expected a net profit of ₹ 298 crore, according to Thomson Reuters I/B/E/S.
Revenue from the company’s generics business in North America, its biggest market, jumped 6% to ₹ 1,590 crore, driven by the US launch of gSuboxone.
Dr.Reddy’s got approval to sell versions of Indivior Plc’s best-selling opioid addiction treatment last month, materially hurting the British drugmaker’s revenue and forcing it to scrap its full-year forecast amid market share loss.
The company also said revenues in US were partly offset by competitive pressure on key molecules as it continues to experience price erosion in the US generics market.
Revenue from its India generics business jumped 30 percent to 6.07 billion rupees. But revenue from its Europe generics business dropped 3 percent to 2.02 billion rupees due to pricing pressures.
Dr Reddy’s shares closed 2.19% higher at ₹ 2134.65 on BSE.